source
- Veradermics reports Phase 3 minoxidil pill boosts hair coverage in menAfter a February IPO that raised more than $256 million and a strong share rally, Connecticut‑based Veradermics now has late‑stage data for its oral minoxidil candidate. In the Phase 3 Study 304,…
- Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trialDisc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study. The trial reported success on every primary and secondary…